Phibro Animal Health (PAHC) Q2 2025 earnings summary

Executive summary

• Q2 consolidated net sales rose 24% year-over-year to $309.3 million, led by the Animal Health segment and the integration of the Zoetis Medicated Feed Additive (MFA) portfolio.

• Adjusted EBITDA increased 64% to $48.2 million, with net income rising to $3.2 million and operating income up 63% to $25.5 million.

• The Zoetis MFA acquisition, completed October 31, 2024, contributed $36.7 million in revenue and expanded the product portfolio and global reach.

• Strong performance attributed to robust demand, portfolio expansion, and operational excellence, with the Phibro Forward initiative supporting efficiency and growth.

• Diversified portfolio and disciplined management position the company for sustainable growth in fiscal 2025 and beyond.

Financial highlights

• Gross profit for the quarter was $101.9 million, up 30% year-over-year, with gross margin improving to 32.9%.

• Adjusted net income for the quarter was $21.9 million, with adjusted diluted EPS of $0.54, both up over 60% year-over-year.

• Free cash flow for the trailing twelve months was $15.3 million; cash and equivalents at $67.1 million.

• Total debt stood at $760.3 million; gross leverage ratio at 3.1x and net leverage ratio at 2.9x.

• Quarterly dividend of $0.12 per share, totaling $4.9 million.

Outlook and guidance

• FY2025 net sales guidance raised to $1.25–$1.3 billion, representing up to 28% growth; adjusted EBITDA guidance $172–$180 million, up to 62% growth.

• Adjusted diluted EPS expected between $1.87 and $2.01, up to 69% year-over-year; GAAP EPS between $0.96 and $1.11.

• Guidance includes Zoetis MFA acquisition, early benefits from Phibro Forward, and assumes no additional foreign exchange gains or losses.

• Adjusted effective tax rate projected at 24–26%.

• Liquidity is considered adequate for at least the next twelve months, with sufficient cash, operating cash flows, and credit facility availability.